Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia
NCT06664125Phase 2Recruiting
- Sponsor
- Jemincare
- Start
- Dec 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of JMKX003002 in hyperphosphatemia (3 arms), sponsored by Jemincare. Primary endpoint: Change in Serum Phosphorus at 4 weeks. Started Dec 2024; status: recruiting.
02
Drugs
JMKX003002
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT06664125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06664125.